CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
Investors who take an interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) should definitely note that the CEO, President & Director, Alexander Sapir, recently paid US$11.35 per share to buy US$492k worth of the stock. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.
View our latest analysis for Fulcrum Therapeutics
The Last 12 Months Of Insider Transactions At Fulcrum Therapeutics
Notably, that recent purchase by Alexander Sapir is the biggest insider purchase of Fulcrum Therapeutics shares that we've seen in the last year. That implies that an insider found the current price of US$12.00 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Fulcrum Therapeutics share holders is that an insider was buying at near the current price. The only individual insider to buy over the last year was Alexander Sapir.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Fulcrum Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Does Fulcrum Therapeutics Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.3% of Fulcrum Therapeutics shares, worth about US$8.9m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
So What Do The Fulcrum Therapeutics Insider Transactions Indicate?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Fulcrum Therapeutics insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Fulcrum Therapeutics. While conducting our analysis, we found that Fulcrum Therapeutics has 2 warning signs and it would be unwise to ignore these.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
